APEX Study: Inhibition of structural damage progression with Guselkumab in PsA Guselkumab, a human IL-23 inhibitor, was evaluated in patients with active PsA and shown to have both clinical and radiographic benefits at weeks 24 and 48. https://t.co/iNEziysnVZ https://t.co/XgFGFfGf3b